KBY Biotech Indexv0.0.34
Search
← Pipeline|Nidaratamab

Nidaratamab

Phase 3
EXE-272
By Exelixis
Source: Trial-derived·Trials: 3
Modality
Radioligand
MOA
AHRant
Target
FLT3
Pathway
PI3K/AKT
AsthmaMM
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
~Apr 2019
→ ~Jul 2020
Phase 3
Oct 2020
→ Aug 2030
Phase 3Current
NCT05092973
1,803 pts·MM
2023-05→2027-03·Completed
NCT08806002
2,495 pts·MM
2020-10→2028-06·Terminated
NCT07679587
1,920 pts·Asthma
2024-10→2030-08·Active
6,218 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2027-03-1111mo awayPh3 Readout· MM
2028-06-112.2y awayPh3 Readout· MM
2030-08-174.4y awayPh3 Readout· Asthma
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Termina…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2027-03-11 · 11mo away
MM
Ph3 Readout
2028-06-11 · 2.2y away
MM
Ph3 Readout
2030-08-17 · 4.4y away
Asthma
ActiveCompletedTerminated|StartCompletionToday
Trials (3)
NCTPhaseIndicationStatusNEP
NCT05092973Phase 3MMCompleted1803EASI-75
NCT08806002Phase 3MMTerminated2495UPCR
NCT07679587Phase 3AsthmaActive1920OS
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-8168Johnson & JohnsonPhase 2/3FLT3GLP-1/GIP
AZN-5978AstraZenecaPhase 2/3GIP-RAHRant
SotorapivirModernaApprovedFLT3TYK2i
BII-5449BiogenPhase 3FXIaAHRant
ElratapinarofHalozymePhase 2C5AHRant
NTL-2576IntelliaNDA/BLASGLT2AHRant
ZanumavacamtenIovancePhase 2FLT3BCL-2i
RAR-440UltragenyxPhase 2FLT3CD3xCD20
TerazumabRapport TherPhase 2BTKAHRant
MotasacituzumabOlemaNDA/BLAFLT3IL-23i